Riskpilot← Back to searchSign inGet full accessApopharmacy AB
ABActiveOrg 5591320030Fyrspannsgatan 164-166Retail sale of pharmaceutical products · NACE 4773Est. 20170 employees
Revenue 2025
SEK 15,2M
-43% vs 2024
EBITDA margin
32.8%
+161% vs 2024
Equity ratio
66.0%
Financial strength
Net profit 2025
SEK 3M
+190% vs 2024
| Revenue | SEK 15,2M | -43% |
| EBITDA | SEK 5M | +161% |
| Net profit | SEK 3M | +190% |
| Total assets | SEK 14,2M | +1% |
| Equity | SEK 9,4M | +46% |
| Employees | 0 | — |
Legal name
Apopharmacy AB
Org number
5591320030
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
2 november 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av externa firmatecknaren
Company purpose
Bolaget ska bedriva apoteks- och hälsokostverksamhet och därmed sammanhörande verksamheter.
Address
Fyrspannsgatan 164-166
Email
jazia.hajo@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 17 233 | 21 152 | 21 183 | 26 494 | 15 155 |
| Staff expenses | — | −2 233 | −1 863 | −1 854 | −839 |
| EBITDA | 2 267 | 2 887 | 1 994 | 1 900 | 4 965 |
| Depreciation & amort. | −73 | −84 | −117 | −173 | −69 |
| EBIT | 2 194 | 2 802 | 1 878 | 1 727 | 4 896 |
| Net financials | −30 | −1 | 2 | 48 | 56 |
| Profit before tax | 1 624 | 2 101 | 1 399 | 1 310 | 3 752 |
| Tax | −349 | −435 | −298 | −288 | −787 |
| Net profit | 1 275 | 1 667 | 1 102 | 1 023 | 2 965 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 10 192 | 10 821 | 10 931 | 14 069 | 14 178 |
| Equity | 3 600 | 5 267 | 5 368 | 6 391 | 9 356 |
| Long-term debt | 964 | 0 | — | — | — |
| Short-term debt | 4 123 | 3 350 | 2 877 | 4 528 | 472 |
| Total debt | 5 087 | 3 350 | 2 877 | 4 528 | 472 |
EBITDA margin
32.8%
This company
15.8%
Market median
+108% vs market
20212025
Equity ratio
66.0%
This company
38.2%
Market median
+73% vs market
20212025
Return on equity
31.7%
This company
18.4%
Market median
+72% vs market
20212025
Net profit margin
19.6%
This company
8.1%
Market median
+142% vs market
20212025
Asset turnover
1.07×
This company
1.12×
Market median
+4% vs market
20212025
Debt / equity
0.52×
This company
0.62×
Market median
+16% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JH External Signatory | External Signatory | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Apopharmacy AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jazia Hajo | External Signatory | 0 companies |
| Peiam Toffik Arif | Deputy Board Member | 0 companies |
| Fatah Toffik Arif | Board of Directors | 0 companies |